journal article·2023-03

Biomimetic Nanobomb for Synergistic Therapy with Inhibition of Cancer Stem Cells

Shuang Liu, Tianshu Zhang, Shanshan Li, Qingyuan Wu, Kexin Wang, Xican Xu, MingZhu Lu, Rongguang Shao, Wuli Zhao, Huiyu Liu

Small· Volume 19· Issue 12
Publisher page

Abstract

Abstract Cancer stem cells (CSCs), a type of cell with self‐renewal, unlimited proliferation, and insensitivity to common physical and chemical factors, are the key to cancer metastasis, recurrence, and chemo‐resistance. Available CSCs inhibition strategies are mainly based on small molecule drugs, yet are limited by their off‐target toxicity. The link between CSCs and non‐CSCs interconversion is difficult to sever. In this work, a nanotherapeutic strategy based on MnOx‐loaded polydopamine (MnOx/PDA) nanobombs with chemodynamic, photodynamic, photothermal and biodegradation properties to inhibit CSCs and non‐CSCs concurrently is reported. The MnOx/PDA nanobombs can directly disrupt the microenvironment and tumorigenic capacity of CSCs by generating hyperthermia, oxidative stress and alleviating hypoxia. The markers of CSCs are subsequently downregulated, leading to the clearance of CSCs. Meanwhile, the synergistic therapy mediated by MnOx/PDA nanobombs can directly ablate the bulk tumor cells, thus cutting off the supply of CSCs transformation. For tumor targeting, MnOx/PDA is coated with macrophage membrane. The final tumor inhibition rate of the synergistic therapy is 70.8% in colorectal cancer (CRC) model. Taken together, the present work may open up the exploration of nanomaterial‐based synergistic therapy for the simultaneous elimination of therapeutically resistant CSCs and non‐CSCs.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Beijing Advanced Innovation Center for Soft Matter Science and Engineering State Key Laboratory of Organic‐Inorganic Composites Bionanomaterials & Translational Engineering Laboratory Beijing Key Laboratory of Bioprocess Beijing Laboratory of Biomedical Materials Beijing University of Chemical Technology Beijing 100029 China

Key Laboratory of Antibiotic Bioengineering Ministry of Health Laboratory of Oncology Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100050 China

Funding

National Basic Research Program of China · National Natural Science Foundation of China

References (44)

Show source-provided references
1. 10.1053/j.gastro.2009.12.06310.1053/j.gastro.2009.12.063 ↗
2. 10.1016/j.addr.2013.09.01610.1016/j.addr.2013.09.016 ↗
3. 10.1002/cac2.1223510.1002/cac2.12235 ↗
4. 10.1053/j.gastro.2009.05.05310.1053/j.gastro.2009.05.053 ↗
5. 10.1016/j.cell.2011.07.02610.1016/j.cell.2011.07.026 ↗
6. 10.1002/ange.20151044310.1002/ange.201510443 ↗
7. 10.3322/caac.2160110.3322/caac.21601 ↗
8. 10.1016/j.addr.2013.07.01210.1016/j.addr.2013.07.012 ↗
9. Takebe N. · Nat. Rev. Cancer · 2010 · 8 · 97
10. 10.1002/EXP.2021008910.1002/EXP.20210089 ↗
11. 10.1002/EXP.2021022310.1002/EXP.20210223 ↗
12. 10.1002/ange.20191147710.1002/ange.201911477 ↗
13. 10.1016/j.biomaterials.2011.12.05210.1016/j.biomaterials.2011.12.052 ↗
14. 10.1002/adfm.20180773310.1002/adfm.201807733 ↗
15. 10.1002/adhm.20140002610.1002/adhm.201400026 ↗
16. 10.1002/adhm.20210227210.1002/adhm.202102272 ↗
17. 10.1016/j.biomaterials.2022.12159810.1016/j.biomaterials.2022.121598 ↗
18. 10.1016/j.biomaterials.2014.02.03510.1016/j.biomaterials.2014.02.035 ↗
19. 10.1002/EXP.2022001410.1002/EXP.20220014 ↗
20. 10.1038/s41467-021-24108-610.1038/s41467-021-24108-6 ↗
21. 10.1002/smll.20210386810.1002/smll.202103868 ↗
22. 10.1021/acsnano.2c0807710.1021/acsnano.2c08077 ↗
23. 10.1002/ange.20201441510.1002/ange.202014415 ↗
24. Guan G. · Angew. Chem., Int. Ed. · 2022 · 13410.1002/ange.202117229 ↗
25. 10.1002/adfm.20210437810.1002/adfm.202104378 ↗
26. 10.1021/cm900431b10.1021/cm900431b ↗
27. 10.1021/jacs.9b0209110.1021/jacs.9b02091 ↗
28. 10.1002/adma.20200356310.1002/adma.202003563 ↗
29. 10.1002/ange.20171202710.1002/ange.201712027 ↗
30. 10.1039/C9TB01400D10.1039/C9TB01400D ↗
31. 10.1038/nrc159010.1038/nrc1590 ↗
32. 10.1038/3510216710.1038/35102167 ↗
33. 10.1016/j.cub.2006.11.03310.1016/j.cub.2006.11.033 ↗
34. 10.1038/ncomms1427010.1038/ncomms14270 ↗
35. 10.1016/j.semcancer.2012.04.00110.1016/j.semcancer.2012.04.001 ↗
36. 10.1073/pnas.201440811810.1073/pnas.2014408118 ↗
37. 10.7150/thno.5100010.7150/thno.51000 ↗
38. 10.1038/nm.243710.1038/nm.2437 ↗
39. 10.1073/pnas.152003211210.1073/pnas.1520032112 ↗
40. 10.1016/j.addr.2020.06.00510.1016/j.addr.2020.06.005 ↗
41. 10.1038/nnano.2015.34210.1038/nnano.2015.342 ↗
42. 10.1038/nrc125610.1038/nrc1256 ↗
43. 10.1021/acsnano.6b0314810.1021/acsnano.6b03148 ↗
44. 10.1002/adfm.20180184010.1002/adfm.201801840 ↗